METHODS OF MANUFACTURING A BIFUNCTIONAL COMPOUND, ULTRAPURE FORMS OF THE BIFUNCTIONAL COMPOUND, AND DOSAGE FORMS COMPRISING THE SAME

The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide,...

Full description

Saved in:
Bibliographic Details
Main Authors REECE, Hayley, REEVE, Maxwell Marco, DONG, Hanqing, ZAHEDI, Mohammad Mehdi, HASKELL, III, Royal J, LLOYD, Rhys, ROBERTSON, Jerod, JAGER, Casey Keith, ALLAN, Laura E.N, REO, Joseph P, GROSSO, John A, KATTUBOINA, Venkata A, KENNEDY, Samuel Elliott, QIU, Yuping, DUGUID, Robert J, KAUSHAL, Aditya Mohan, NEESER, Miranda Annell, CHEN, Chungpin Herman
Format Patent
LanguageEnglish
French
German
Published 15.03.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A:The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer.
Bibliography:Application Number: EP20210730706